Bamco Inc. NY Has $971.67 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bamco Inc. NY reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,923,258 shares of the company's stock after selling 112,079 shares during the period. IDEXX Laboratories makes up about 2.6% of Bamco Inc. NY's portfolio, making the stock its 8th biggest holding. Bamco Inc. NY owned approximately 2.35% of IDEXX Laboratories worth $971,668,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in IDXX. Chicago Partners Investment Group LLC lifted its position in IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after purchasing an additional 96 shares during the period. Manning & Napier Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $20,418,000. Oppenheimer Asset Management Inc. raised its holdings in shares of IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after buying an additional 1,453 shares in the last quarter. National Pension Service lifted its holdings in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after acquiring an additional 12,647 shares during the last quarter. Finally, EFG Asset Management Americas Corp. boosted its position in IDEXX Laboratories by 45.3% in the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after buying an additional 3,966 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Stifel Nicolaus cut their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Finally, Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday. They issued an "outperform" rating and a $500.00 price target for the company. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $546.56.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Up 2.0 %

NASDAQ:IDXX traded up $8.33 during trading hours on Monday, reaching $430.08. The company had a trading volume of 376,540 shares, compared to its average volume of 505,075. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The firm has a market cap of $35.22 billion, a price-to-earnings ratio of 40.67, a P/E/G ratio of 3.68 and a beta of 1.36. The business's 50-day simple moving average is $451.91 and its two-hundred day simple moving average is $477.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same period in the previous year, the company posted $2.53 EPS. The firm's revenue was up 6.6% compared to the same quarter last year. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.